Answers are grounded in this paper and cite their sources.
Jennifer S. Michaelson, Chief Scientific Officer at Cullinan Oncology, and Patrick A. Baeuerle, scientific advisor to Cullinan Oncology and honorary professor in immunology at Ludwig Maximilians University Munich, discuss the use of CD19-specific T cell–engaging antibody therapies (TCEs) as therapeutics for autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Michaelson et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: